Dr. Beth M. Warren, MD
Pediatric Hematology & Oncology (Pediatric Hematology & Oncology Physician)
13199 E Montview Blvd
Aurora, CO 80045
Who else practices at this address →
Adams County includes primary care (2% of residents) shortage areas. About shortage areas
At a glance
- Medical school
- University of Texas Southwestern Medical School at Dallas (2009)
- Years since graduation
- 17
- In the NPI registry since
- 2009
Licensed in Colorado since 2012, according to the Colorado Department of Regulatory Agencies. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2009Medical school: University of Texas Southwestern Medical School at Dallas
- 2009Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Hematology & Oncology Physician primary
CO license 0051004 (first issued 2012; transferred to compact physician) -
Hematology & Oncology Physician
CO license 0051004 (first issued 2012; transferred to compact physician)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- University Physicians Incorporated (3,215 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Payments from drug and device companies
In 2025, 1 companies reported 8 payments worth $8,411 in total to this clinician.
| Genentech USA, Inc. | $8,411 |
|---|
| Consulting Fee | $6,970 |
|---|---|
| Travel and Lodging | $973 |
| Food and Beverage | $468 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genentech USA, Inc. Oct 24, 2025 | Consulting Fee Hemlibra · Hematology | $6,970 |
| Genentech USA, Inc. Oct 24, 2025 | Travel and Lodging Hemlibra · Hematology · travel to Salt Lake City, UT · in-kind | $591 |
| Genentech USA, Inc. Oct 24, 2025 | Travel and Lodging Hemlibra · Hematology · travel to Salt Lake City, UT · in-kind | $304 |
| Genentech USA, Inc. Oct 24, 2025 | Travel and Lodging Hemlibra · Hematology · travel to Salt Lake City, UT · in-kind | $77.93 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $38,964 in research payments for these studies, mostly to the institutions running them.
- An open label study to determine PK and PD of Hemlibra in severe hemophilia A without inhibitors
Genentech, Inc. - A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A
Sanofi US Services Inc. · Active, not recruiting · NCT05911763
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.